Related Experiment Video
Updated: Dec 29, 2025
06:23
A Murine Orthotopic Bladder Tumor Model and Tumor Detection System
Published on: January 12, 2017
15.4K
Prostate-Specific Antigen Test Utilization in a Major Canadian City
Qunfeng Wang1, Fang Chen2, Depeng Jiang3
1Diagnostic Services, Shared Health Manitoba, Winnipeg, Canada.
American Journal of Clinical Pathology
|February 1, 2020
Summary
Prostate-specific antigen (PSA) testing rates are declining in Winnipeg, falling below optimal utilization. This study highlights the need to reinforce clinical recommendations for appropriate PSA screening.
Area of Science:
- Urology
- Public Health
- Health Services Research
Background:
- Prostate-specific antigen (PSA) testing is a key tool in prostate cancer screening.
- Understanding PSA testing utilization patterns is crucial for optimizing patient care and resource allocation.
Purpose of the Study:
- To review prostate-specific antigen (PSA) testing utilization in Winnipeg.
- To compare PSA testing rates in Winnipeg with those in Calgary, a comparable Canadian city.
Main Methods:
- Retrospective review of PSA testing data by year and age group.
- Analysis focused on 2011 and 2016, utilizing available census demographic data.
- Comparison of PSA testing rates between Winnipeg and Calgary.
Main Results:
- Winnipeg showed a declining trend in PSA testing rates from 2008 to 2017.
- PSA testing rates in 2016 were lower than in 2011 across most age groups, with 14-20% decreases for men over 40.
- In 2011, Winnipeg's PSA testing rates were 36-50% higher than Calgary's for men over 40.
Conclusions:
- Current PSA testing utilization in Winnipeg may not align with optimal clinical recommendations.
- Reinforcement of evidence-based guidelines for PSA testing is necessary to ensure appropriate screening practices.
